Abstract

The purpose of this study was to determine the plasmid architecture and context of resistance genes in multi-drug resistant (MDR) Escherichia coli strains isolated from urinary tract infections in dogs. Illumina and single-molecule real-time (SMRT) sequencing were applied to assemble the complete genomes of E. coli strains associated with clinical urinary tract infections, which were either phenotypically MDR or drug susceptible. This revealed that multiple distinct families of plasmids were associated with building an MDR phenotype. Plasmid-mediated AmpC (CMY-2) beta-lactamase resistance was associated with a clonal group of IncI1 plasmids that has remained stable in isolates collected up to a decade apart. Other plasmids, in particular those with an IncF replicon type, contained other resistance gene markers, so that the emergence of these MDR strains was driven by the accumulation of multiple plasmids, up to 5 replicons in specific cases. This study indicates that vulnerable patients, often with complex clinical histories provide a setting leading to the emergence of MDR E. coli strains in clonally distinct commensal backgrounds. While it is known that horizontally-transferred resistance supplements uropathogenic strains of E. coli such as ST131, our study demonstrates that the selection of an MDR phenotype in commensal E. coli strains can result in opportunistic infections in vulnerable patient populations. These strains provide a reservoir for the onward transfer of resistance alleles into more typically pathogenic strains and provide opportunities for the coalition of resistance and virulence determinants on plasmids as evidenced by the IncF replicons characterised in this study.

Highlights

  • E. coli is an important commensal organism and a significant pathogen

  • As previously described (Wagner et al, 2014) multi-drug resistant (MDR) isolates are often associated with animals with complex medical histories and understanding their emergence in the context of generally sensitive E. coli isolates (AS) provides an important opportunity to develop our understanding of MDR emergence in a clinical setting

  • Phenotypic beta-lactamase resistance is attributed to plasmid mediated AmpC (pAmpC), encoded exclusively by the CMY-2 allele on IncI1 replicon plasmids, forming a notably closely related phylogenetic cluster, with high levels of homogeneity in the IncI1 plasmid sequence, despite the strains having been collected over a 10 year period

Read more

Summary

Introduction

E. coli is an important commensal organism and a significant pathogen It is associated with intestinal and extra-intestinal infections and is a leading cause of urinary tract infections (UTIs) and bacteraemia leading to sepsis (Pitout, 2010). Beta-lactam antimicrobials are widely used in both human and animal medicine Due to their spectrum of activity, pharmacokinetic characteristics and good safety profile, members of the group are a good choice in the treatment of UTIs associated with E. coli. There is increasing resistance to these antimicrobials, mediated by the ability of Enterobacteriaceae such as E. coli, to produce plasmid mediated AmpC (pAmpC) and extended spectrum beta-lactamase enzymes (ESBLs). This imparts resistance to most of the Beta-lactam antimicrobials, including the later generation cephalosporins. Less information is available for companion animals, but studies that have evaluated this report a resistance epidemiology similar to that observed in human clinical care (Dierikx et al, 2012; Gibson et al, 2010; Murphy et al, 2010; Tamang et al, 2012)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call